Showing results (31-40 of 157) with videos related to
Sort By:
Pageof 16
The Journal of Rheumatology. Supplement|November 3, 2011
Validity of quality of life measurement tools--from generic to disease-specificGeorge A Wells, Anthony S Russell, Boulos Haraoui, et al.The Journal of Rheumatology|December 3, 2013
Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER studyEdward C Keystone, Boulos Haraoui, Benoît Guérette, et al.Arthritis Research & Therapy|September 27, 2023
Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abataceptLouis Bessette, Boulos Haraoui, Emmanouil Rampakakis, et al.The Journal of Rheumatology|October 17, 2007
Advantages and limitations of utility assessment methods in rheumatoid arthritisAriel Beresniak, Anthony S Russell, Boulos Haraoui, et al.Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|November 7, 2002
Etiology and outcome of acute liver failure: experience from a liver transplantation centre in MontrealGeneviève Tessier, Edith Villeneuve, Jean-Pierre VilleneuveJournal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|February 25, 2014
Treating rheumatoid arthritis to target: a Canadian patient surveyBoulos Haraoui, William Bensen, Carter Thorne, et al.Current Medical Research and Opinion|March 26, 2009
Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational studyClifton O Bingham, Akgun Ince, Boulos Haraoui, et al.Arthritis Care & Research|March 20, 2013
Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trialJanet E Pope, Boulos Haraoui, Emmanouil Rampakakis, et al.Arthritis Research & Therapy|June 8, 2019
Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registryDenis Choquette, Louis Bessette, Evo Alemao, et al.Arthritis Research & Therapy|December 17, 2017
Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatmentJeffrey R Curtis, Kevin Winthrop, Cathy O'Brien, et al.Pageof 16